Investor Alert

Market Pulse Archives

March 9, 2021, 8:38 a.m. EST

Acadia Pharmaceuticals stock leads premarket losers after FDA finds undisclosed 'deficiencies' in NDA

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    ACADIA Pharmaceuticals Inc. (ACAD)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Acadia Pharmaceuticals Inc. /zigman2/quotes/205236646/composite ACAD +2.69% plunged 42.1% to pace all premarket decliners Tuesday, in the wake of the company's announcement that the Food and Drug Administration found undisclosed deficiencies in its supplemental New Drug Application (NDA) for pimavanserin, a treatment for hallucinations and delusions associated with dementia-related psychosis. The company said late Monday that the FDA's identification of deficiencies precluded discussion of labeling and post-marketing requirements. But the FDA did not specify the deficiencies it identified, Acadia said. That led Raymond James analyst Danielle Brill to downgrade Acadia to outperform from strong buy and slash the price target to $35 from $65. "We have no good guesses as to what 'deficiencies' the FDA found, but one thing is clear -- the regulatory outlook for DRP suddenly appears quite dire," Brill wrote in a note to clients. Stifel Nicolaus's Paul Matteis cut his rating to hold from buy and his price target to $27 from $68. "Not defending the stock on weakness; DRP prospects seem bleak, tough for us to be confident," Matteis wrote. The stock, which is on track to open at the lowest price seen during regular-session hours since September 2019, has lost 12.5% over the past three months through Monday, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +2.43% has gained 4.0%.

US : U.S.: Nasdaq
$ 22.11
+0.58 +2.69%
Volume: 1.20M
Jan. 28, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$3.46 billion
Rev. per Employee
+105.34 +2.43%
Volume: 2.91B
Jan. 28, 2022 4:54p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.